Sagimet Publishes on Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in MASH

  Treatment with denifanstat achieved statistically significant and clinically meaningful improvements in disease activity, MASH resolution and fibrosis -

- Results support advancement of denifanstat into Phase 3 development -

https://www.globenewswire.com/news-release/2024/10/11/2961935/0/en/Sagimet-Biosciences-Announces-Publication-of-Results-from-Phase-2b-FASCINATE-2-Clinical-Trial-of-Denifanstat-in-Biopsy-Confirmed-F2-F3-MASH-in-The-Lancet-Gastroenterology-Hepatolog.html